This made the anti-apoptotic protein an attractive cancer therapeutic target and several classes of agents, including CDK9 and direct MCL1 inhibitors, are now being tested in clinical trials [reviewed in refs: 61,62]. The gene discussed is CDK9; the disease is cancer.